CLS granted patent in China for the product and method of controlling treatment with imILT protocol
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) has received a new patent registration in China. The patent is titled "Temp feedback controlled cooled probe" and corresponds to the European patent "Apparatus and Method for Controlling Immunostimulating Laser Thermotherapy" which was granted in 2019.
“As with the corresponding patent in Europe, the aim with the China patent is to remove any opportunity for competitors to develop both cooled and non-cooled fiber for our imILT protocol. CLS’s non-cooled fiber has a unique position, and we want to ensure we retain that position,” says Stephan Dymling, Chief Technical Officer, CLS.
“The new patent provides enhanced protection against competing fiber manufacturers. CLS now has patents in China covering important technology for a system that includes both cooled and non-cooled fiber adapted for the imILT protocol,” says Stephan Dymling.
imILT is CLS’s own specific immune stimulating ablation protocol for the treatment of cancer. The imILT immunotherapy protocol is currently in the early phase of clinical studies.
The Chinese patent is valid until 2034 and protects the CLS technology for controlling heat treatment according to the CLS imILT protocol - a protocol that involves a heating period followed by a treatment period. In addition to China and Europe, CLS also holds a patent in the US for the same technology.
The patent covers both MRI treatments, where real time temperature image maps are directly derived from the MRI images, and ultrasound-guided treatments where a separate probe is positioned in the tissue.
CLS aims to ensure protection for its entire patent portfolio across all strategic markets, including the US, Europe and Asia Pacific.
The information was submitted for publication on March 23, 2022 at 12:00 CET.
Contact Information:
Lars-Erik Eriksson, CFO and Deputy CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 – (0)702 – 90 33 00 E-mail: lars-erik.eriksson@clinicallaser.com
About CLS and TRANBERG system
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
Tags: